Canaccord analyst William Plovanic lowered the firm’s price target on Tandem Diabetes (TNDM) to $58 from $63 and keeps a Buy rating on the shares. The firm said they delivered a solid overall Q4/24 but guidance came in a little light and more conservative than expected. In context, management is broadcasting FY25 as a transition year with a pipeline of important products, launches, and enhancements, colored by a US salesforce realignment in 1H/25 and a transition to a direct sales model OUS impacting 2H/25.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes Care: FDA Approval and Strategic Growth Opportunities Drive Buy Rating
- Tandem Diabetes Care Reports Record 2024 Sales Growth
- Tandem Diabetes Care: Strong International Sales and Promising 2025 Outlook Justify Buy Rating
- Tandem Diabetes sees Q1 revenue $219M-$224M, consensus $220.7M
- Tandem Diabetes sees FY25 revenue $997M to $1.01B, consensus $1.01B